新浪登录
腾讯登录23andMe成立医疗学团队
| 导读 | 23andMe今日宣布该公司完成了其治疗学团队的建立，该团队由基因泰克前总裁Richard Scheller领军。 |
23andMe今日宣布该公司完成了其治疗学团队的建立，该团队由基因泰克前总裁Richard Scheller领军。治疗学团队的建立意味着这家曾经以消费者基因组检测服务为核心的公司正式转型成为药物研发公司。
基因泰克前科研执行副总裁Richard Scheller去年十二月份从该公司退休，从今年四月开始，他将正式出任23andMe首席科学家与治疗学团队带头人。与此同时，Richard Scheller将领导一支应用基因组信息为常规与罕少见疾病制定新型疗法的研发团队。这支研发团队的工作将充分体现23andMe所拥有的超过85万消费者基因型数据库极大价值。
23andMe CEO Anne Wojcicki在声明中表示：“我们将运用我们所拥有的巨大基因组数据库来实现基因组信息向新型分子治疗方法的转变，更好地服务于我们的客户乃至全世界需要我们的人。” 23andMe主席Andy Page 则表示该公司正为其新的努力方向积极筹建研发团队。
在基因泰克任职期间，Richard Scheller主要监管该公司的肿瘤学、免疫学、神经科学与感染性相关疾病的研究。Richard Scheller担任斯坦福大学生物学以及分子细胞物理学教授长达19年之久。同时，Richard Scheller也是斯坦福大学医学中心霍华德休斯医学研究所股东之一。
两年前，Richard Scheller因其对神经递质快速释放的发现与机制阐明荣获著名的阿尔伯特·拉斯克基础医学研究奖。（转化医学网360zhyx.com）
以上为转化医学网原创翻译整理，如需转载，请联系 info@360zhyx.com 。
原文：（genomeweb）
23andMe announced today that it has created a therapeutics group headed up by former Genentech executive Richard Scheller, marking the consumer genomics firm's foray into drug development.
Scheller, who was executive VP of research and early development at Genentech, retired last December from the biotech giant. In April, he will assume his post as chief science officer and head of therapeutics at 23andMe, and will be in charge of an R&D team that will use genetic information to advance new treatments for common and rare illnesses. Key to this work will be 23andMe's database of more than 850,000 genotyped customers.
"We are putting significant resources into translating genetic information into the discovery and development of new therapies for our customers and the world," said 23andMe CEO Anne Wojcicki in a statement. 23andMe President Andy Page noted the company is working on recruiting a team of researchers for this new effort.
At Genentech, Scheller oversaw basic research in oncology, immunology, neuroscience, and infectious disease. At Stanford University for 19 years, he was a professor in the department of biological sciences and the department of molecular and cellular physiology. He was also an investigator at the Howard Hughes Medical Institute of Stanford University Medical Center.
Two years ago, Scheller received the prestigious Albert Lasker Basic Medical Research Award for his discovery efforts elucidating the molecular and regulatory mechanisms involved in the rapid release of neurotransmitters.
基因泰克前科研执行副总裁Richard Scheller去年十二月份从该公司退休，从今年四月开始，他将正式出任23andMe首席科学家与治疗学团队带头人。与此同时，Richard Scheller将领导一支应用基因组信息为常规与罕少见疾病制定新型疗法的研发团队。这支研发团队的工作将充分体现23andMe所拥有的超过85万消费者基因型数据库极大价值。
23andMe CEO Anne Wojcicki在声明中表示：“我们将运用我们所拥有的巨大基因组数据库来实现基因组信息向新型分子治疗方法的转变，更好地服务于我们的客户乃至全世界需要我们的人。” 23andMe主席Andy Page 则表示该公司正为其新的努力方向积极筹建研发团队。
在基因泰克任职期间，Richard Scheller主要监管该公司的肿瘤学、免疫学、神经科学与感染性相关疾病的研究。Richard Scheller担任斯坦福大学生物学以及分子细胞物理学教授长达19年之久。同时，Richard Scheller也是斯坦福大学医学中心霍华德休斯医学研究所股东之一。
两年前，Richard Scheller因其对神经递质快速释放的发现与机制阐明荣获著名的阿尔伯特·拉斯克基础医学研究奖。（转化医学网360zhyx.com）
以上为转化医学网原创翻译整理，如需转载，请联系 info@360zhyx.com 。
原文：（genomeweb）
23andMe announced today that it has created a therapeutics group headed up by former Genentech executive Richard Scheller, marking the consumer genomics firm's foray into drug development.
Scheller, who was executive VP of research and early development at Genentech, retired last December from the biotech giant. In April, he will assume his post as chief science officer and head of therapeutics at 23andMe, and will be in charge of an R&D team that will use genetic information to advance new treatments for common and rare illnesses. Key to this work will be 23andMe's database of more than 850,000 genotyped customers.
"We are putting significant resources into translating genetic information into the discovery and development of new therapies for our customers and the world," said 23andMe CEO Anne Wojcicki in a statement. 23andMe President Andy Page noted the company is working on recruiting a team of researchers for this new effort.
At Genentech, Scheller oversaw basic research in oncology, immunology, neuroscience, and infectious disease. At Stanford University for 19 years, he was a professor in the department of biological sciences and the department of molecular and cellular physiology. He was also an investigator at the Howard Hughes Medical Institute of Stanford University Medical Center.
Two years ago, Scheller received the prestigious Albert Lasker Basic Medical Research Award for his discovery efforts elucidating the molecular and regulatory mechanisms involved in the rapid release of neurotransmitters.
还没有人评论，赶快抢个沙发